169 related articles for article (PubMed ID: 38381215)
1. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
[TBL] [Abstract][Full Text] [Related]
2. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract][Full Text] [Related]
3. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
5. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
[TBL] [Abstract][Full Text] [Related]
6. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
7. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
8. Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
Liang S; Zhou X; Cai D; Rodrigues-Lima F; Wang L
Curr Pharm Des; 2021; 27(26):2990-2998. PubMed ID: 34218775
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway.
Gao G; Xue Q; He J; Wu M; Jiang Y; Li Q; Zhang Y; Shi W
Int Immunopharmacol; 2023 Dec; 125(Pt A):111125. PubMed ID: 37907047
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
11. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
12. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
13. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
14. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
15. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.
He W; Xu Z; Song D; Zhang H; Li B; Gao L; Zhang Y; Feng Q; Yu D; Hu L; Chen G; Tao Y; Wu X; Shi J; Zhu W
Life Sci; 2020 Feb; 243():117249. PubMed ID: 31926247
[TBL] [Abstract][Full Text] [Related]
17. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
18. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
20. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]